Quote:Utilizing a >400 RFU threshold, treatment with leronlimab was associated with the upregulation of PD-L1 in CTCs and cancer-associated macrophage-like cells (CAMLs) in 76% (n=16/21) of patients overall, and 88% (n=15/17) of patients who received leronlimab at a dose of 525 mg or 700 mg.
88% is awesome for dosing >525 mg but is it 100% for those who received 700 mg?
Did someone run those numbers from the ESMO poster previously?